OLAM: Oral LisdexAmphetamine for Methamphetamine Use Disorder

Oral Lisdexamfetamine for the treatment of Acute Methamphetamine withdrawal (the OLAM trial): A randomised controlled trial.

Overview

This study is testing whether lisdexamfetamine, a medication currently used for ADHD, can safely and effectively reduce withdrawal symptoms when people stop using methamphetamine. At present, there is no proven medication to help with methamphetamine withdrawal, and this research builds on earlier findings showing that lisdexamfetamine is safe and feasible in this setting. By comparing lisdexamfetamine with a placebo, the trial aims to discover if it can make withdrawal more manageable.

Participants will be admitted to the Turning Point Addiction Medicine Unit (TPAMU) at Box Hill Hospital for a medically supervised seven-day stay. Everyone will receive the usual high standard of inpatient care, including medical and nursing support, psychosocial services, and help with ongoing treatment planning, while also receiving either lisdexamfetamine or a placebo as part of the study.

Expressions of interest

If you would like to refer someone or want more information, please contact the team at [email protected].

Project team

Turning Point team

Assoc Prof Shalini Arunogiri and Prof Dan Lubman. 

Project partners

Professor Nadine Ezard, St Vincents Hospital Sydney (SVHS) and The University of New South Wales (UNSW)

Our sponsor

This trial is sponsored by St Vincent’s Hospital Sydney (SVHS) and The University of New South Wales (UNSW)